Major Pharmaceutical Manufacturer Partners with Mellifiq to Treat Pharmaceutical Residues

One of the world’s largest pharmaceutical manufacturers has completed its third full-scale pilot together with Mellifiq, evaluating advanced ozonation for the removal of pharmaceutical residues in process water prior to discharge.

The objective of the project was to break down high concentrations of pharmaceutical compounds in the wastewater stream generated during production. The treated substances include compounds used in medications for diabetes, bacterial infections, hypertension, and depression.

As global pharmaceutical use continues to increase, preventing residues from entering wastewater systems and ultimately the natural environment has become an important environmental priority. By applying Mellifiq’s advanced ozone-based oxidation process, removal efficiencies exceeding 99% were achieved for the targeted substances.

Mellifiq expects the order for a full-scale installation to be placed during the year, with commissioning anticipated in Q1 next year.